China Biotech Services Achieves First Beam Emission with BNCT Device
Reuters
Nov 25
China Biotech Services Achieves First Beam Emission with BNCT Device
China Biotech Services Holdings Ltd. announced that its NeuCure® neutron irradiation system, the core device for boron neutron capture therapy (BNCT) at the Pengbo (Hainan) BNCT Hospital, has successfully performed its first beam emission. This milestone marks the transition of the project from equipment installation to the clinical commissioning phase, verifying that the system's core components meet design specifications. The company stated that the BNCT system is currently the only one in the world with a formal medical device registration certificate and is ready for regular clinical treatment, with related services expected to commence in the first quarter of 2026. These results have just been achieved and announced by the company; they have not yet been presented elsewhere.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Biotech Services Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251125-11928119), on November 25, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.